HC Wainwright Reiterates “Buy” Rating for Aemetis (NASDAQ:AMTX)

Aemetis (NASDAQ:AMTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $28.00 price objective on the specialty chemicals company’s stock.

A number of other research firms have also issued reports on AMTX. StockNews.com upgraded shares of Aemetis to a “sell” rating in a research note on Wednesday, July 31st. Truist Financial reiterated a “hold” rating and issued a $3.50 price objective (down previously from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. Ascendiant Capital Markets lowered their target price on Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, UBS Group cut their price target on Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a research note on Monday, August 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Aemetis has an average rating of “Moderate Buy” and a consensus target price of $12.95.

Aemetis Trading Down 5.9 %

Shares of Aemetis stock opened at $3.83 on Friday. The company has a fifty day moving average price of $2.80 and a 200 day moving average price of $3.06. Aemetis has a twelve month low of $2.10 and a twelve month high of $7.03. The stock has a market cap of $190.50 million, a price-to-earnings ratio of -1.69 and a beta of 1.23.

Aemetis (NASDAQ:AMTX) last issued its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million during the quarter, compared to analysts’ expectations of $77.79 million. During the same period in the previous year, the company earned ($0.59) EPS. Analysts forecast that Aemetis will post -2.1 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Aemetis during the 1st quarter worth approximately $60,000. State Board of Administration of Florida Retirement System bought a new position in Aemetis during the first quarter worth $84,000. Bank of New York Mellon Corp acquired a new position in Aemetis in the second quarter worth $306,000. Rhumbline Advisers increased its stake in Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after purchasing an additional 50,528 shares during the last quarter. Finally, Hutchinson Capital Management CA acquired a new stake in shares of Aemetis during the second quarter worth $70,000. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.